RT Journal Article
SR Electronic
T1 Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 355
OP 360
DO 10.2967/jnumed.115.165613
VO 57
IS 3
A1 Marlies Michl
A1 Sebastian Lehner
A1 Philipp M. Paprottka
A1 Harun Ilhan
A1 Peter Bartenstein
A1 Volker Heinemann
A1 Stefan Boeck
A1 Nathalie L. Albert
A1 Wolfgang P. Fendler
YR 2016
UL http://jnm.snmjournals.org/content/57/3/355.abstract
AB We evaluated the prognostic accuracy of established PET response criteria in patients with liver metastases from pancreatic cancer after treatment with 90Y microspheres. Methods: Seventeen patients underwent 18F-FDG PET/CT before and 3 mo after radioembolization for liver metastases from pancreatic cancer. Overall survival, progression-free survival, and time to intrahepatic progression were among other factors correlated with metabolic response as revealed by PERCIST 1.0–defined declining SUVpeak and total-lesion glycolysis. Results: Metabolic response by change in SUVpeak (7/17) and change in total-lesion glycolysis (7/17) was a predictor for overall survival (P = 0.039; hazard ratio [HR], 0.24; 95% confidence interval [CI], 0.06–0.93), progression-free survival (P = 0.016; HR, 0.15; 95% CI, 0.03–0.69), and time to intrahepatic progression (P = 0.010; HR, 0.16; 95% CI, 0.04–0.65). A summed baseline CT diameter of less than 8 cm for the 2 largest liver metastases predicted time to intrahepatic progression (P = 0.013; HR, 0.21; 95% CI, 0.06–0.72) but did not predict overall or progression-free survival. Patient outcome was not predicted by other parameters, including baseline SUVpeak, baseline total-lesion glycolysis, or change in serum level of carcinoembryonic antigen or carbohydrate antigen 19-9 from baseline to follow-up (each, P > 0.05). Conclusion: Metabolic response by 18F-FDG PET/CT predicts overall survival, progression-free survival, and time to intrahepatic progression after radioembolization for liver metastases from pancreatic cancer.